Skip to content
All Sections
Subscribe Now
71°F
Friday, September 26th 2025
e-Edition
Home Page
News
News
Crime and Public Safety
Investigative Reporting
Election
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Weather
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
Sponsored Content
Branded Content
Paid Content by Brandpoint
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
71°F
Friday, September 26th 2025
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
High school football ð
Immigration news
How to get Olympics tickets ðð¼
Trump news
Weather news
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Compass Pathways plc
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
April 22, 2025
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
March 26, 2025
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
March 18, 2025
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Compass Pathways to Participate in Stifel Virtual CNS Forum
March 11, 2025
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights
February 27, 2025
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference
February 25, 2025
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
February 18, 2025
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 05, 2025
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer
January 21, 2025
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Compass Pathways Announces Pricing of Underwritten Offering
January 10, 2025
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)
December 18, 2024
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Compass Pathways to Participate in December Investor Conferences
November 25, 2024
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates
October 31, 2024
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024
October 24, 2024
From
Compass Pathways plc
Via
Business Wire
Tickers
CMPS
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
Close